The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis
about
Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomesOutcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature reviewHead-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasisBreast cancer resistance protein in pharmacokinetics and drug-drug interactions.Methotrexate in dermatology.In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study.Drug repositioning in the treatment of malaria and TB.The use of methotrexate in dermatology: a review.Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate.Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease.Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism.Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.A HPLC-SRM-MS based method for the detection and quantification of methotrexate in urine at doses used in clinical practice for patients with rheumatological disease: a potential measure of adherence
P2860
Q26768683-813FF878-964A-4285-999D-A09049C03C72Q26995202-B3B2F300-57B8-45B2-8911-ACDEACB5A7C8Q33956370-E68A2A98-BDD4-4DD3-B343-876142CD540FQ35803952-1617C528-EC3B-4F53-835D-4BAD180AE583Q36544862-B97D80FC-A038-40ED-A79D-AA560E0D5FDAQ36986025-DA32A9D2-B1CC-47A0-B6E8-F435CAE4006DQ37333178-02394125-8874-46B9-B5C1-AA35F8B52918Q37587400-3A9EE287-1608-485A-9236-E5B7562D5E5DQ37924298-43765369-00BD-4D98-B844-10CCBA7665DAQ37981730-FE55B422-84D4-43F5-BD24-302F4906F263Q38991972-1A640F7B-B9C7-4C0D-AC48-8F5B2717F582Q39181492-6222554D-22BF-4B55-A603-14DC936C2A47Q44140105-CC6742F1-B74B-492F-A956-C87FD537549DQ44505159-D192F850-1BA3-4F60-8E4A-C2D8A50A03C1Q50047899-05CB7E99-FF8C-4DA3-8A65-0281A24D946BQ50565052-1A89AD90-008B-4B0E-B1D5-3FE9AFA365E8Q57323555-2E84D8DD-EFD7-4861-A721-4BD168AC975F
P2860
The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis
@ast
The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis
@en
type
label
The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis
@ast
The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis
@en
prefLabel
The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis
@ast
The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis
@en
P2093
P2860
P1476
The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis
@en
P2093
P2860
P304
P356
10.1046/J.1365-2125.1998.T01-1-00790.X
P407
P577
1998-10-01T00:00:00Z